to evaluate the influence of the angiotensin-converting enzyme inhibitor , enalapril ( 2.5 to 40 mg/day ) , on the prognosis of severe congestive heart failure , defined as new york heart association functional class iv , a double-blind study was undertaken in which 253 patients were randomized to receive either placebo ( n = 126 ) or enalapril ( n = 127 ) in addition to conventional treatment , including vasodilators .
C0018802
congestive heart
C0014025
enalapril